Enteric Rapamycin Formulations for Stable Oral Bioavailability in Pets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rapamycin, an mTOR inhibitor, is poorly soluble in water, undergoes high efflux in the intestines, and degrades rapidly at gastric pH, leading to variable pharmacokinetics and low bioavailability, making it challenging to effectively treat cardiovascular diseases and aging-related issues in companion animals.
Innovation Solution
Development of veterinary formulations of rapamycin, including a dispersion with a binder and polymer, and a gastro-resistant coating, to improve solubility and stability, allowing for effective administration in companion animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rapamycin is administered orally in conventional formulations, then it can be delivered to companion animals, but it degrades rapidly in the stomach due to acid-lability and shows poor solubility, resulting in low bioavailability and highly variable pharmacokinetics
Solution Approach 1:
The patent employs an enteric coating as an intermediary protective layer that prevents direct contact between rapamycin and gastric acid. The coating acts as a mediator that allows the drug to pass through the stomach intact and only dissolves in the more neutral environment of the intestine, thereby protecting the acid-labile rapamycin from degradation and improving its bioavailability.
Solution Approach 2:
The patent modifies the environmental parameters (pH conditions) under which rapamycin is released by using pH-sensitive enteric coating materials. The coating remains intact in the acidic stomach environment (pH 1-3) but dissolves at higher intestinal pH (above 5.5), thereby changing the release parameters of the drug to match the appropriate physiological environment for absorption.
2Reliability
If rapamycin is formulated for oral administration, then it can reach the intestines for absorption, but it undergoes high efflux and maintains poor solubility, leading to inconsistent pharmacokinetic profiles
Solution Approach 1:
The patent uses composite material approaches by combining rapamycin with solubility-enhancing excipients and incorporating it into a structured delivery system comprising core, matrix, and coating layers. This composite formulation improves the solubility and dissolution characteristics of rapamycin while maintaining stable composition throughout the gastrointestinal tract.
Solution Approach 2:
The patent applies local quality principles by creating different functional zones within the tablet structure - the enteric coating provides acid resistance in the stomach region, while the matrix composition is optimized for controlled release in the intestine. Each part of the formulation has tailored properties suited for its specific location and function in the gastrointestinal tract.
3Quantity of substance
If conventional oral formulations are used, then administration is simple, but the combination of poor solubility, high efflux, and acid degradation results in low and variable drug delivery to target tissues
Solution Approach 1:
The patent divides the tablet into distinct functional segments: an inner core containing rapamycin, a matrix layer providing controlled release and solubility enhancement, and an outer enteric coating providing acid protection. This segmentation allows each component to perform its specific function optimally, ensuring sufficient drug delivery despite the increased formulation complexity.
Data Source
AI summary
The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.